The injection is the generic therapeutic equivalent of the US Food and Drug Administration (US FDA)-approved Lexiscan (Regadenoson) injection. To test the heart for coronary artery disease, the injection is utilised.
Hyderabad: Dr. Reddy’s Laboratories Ltd. (Dr Reddy’s), announced the launch of Regadenoson Injection in the US market.
The injection is the generic therapeutic equivalent of the US Food and Drug Administration (US FDA)-approved Lexiscan (Regadenoson) injection.
According to Dr Reddy’s, the Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).
To test the heart for coronary artery disease, the injection is utilised.
Lexiscan is a registered trademark of Astellas US LLC.
